Voxelotor-d6

Voxelotor-d6 (GBT 440-d6) is deuterium labeled Voxelotor. Voxelotor (GBT 440) is a potent inhibitor of haemoglobin S (HbS) polymerization. Voxelotor has the potential for sickle cell disease (SCD) treatment[1].

2170187-39-8

GBT 440-d6

12352005

Isotope-Labeled Compounds

Others

Neuroscience-Neuromodulation

Cardiovascular Disease

O=CC(C(O)=CC=C1)=C1OCC2=C(C3=CC=NN3C(C([2H])([2H])[2H])C([2H])([2H])[2H])N=CC=C2

C19H13D6N3O3

343.41

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Oksenberg D, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016 Oct;175 (1) :141-53.|[3]Metcalf B, Chuang C, Dufu K, et al. Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin. ACS Med Chem Lett. 2017;8 (3) :321-326.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-18681S/

Isotope-Labeled Compounds

No Development Reported